Dr. Scott L. Friedman: “Drug Improves Nonalcoholic Steatohepatitis, With Caveats”
A bile acid derivative, obeticholic acid (OCA), improves nonalcoholic steatohepatitis (NASH), according to a study published online November 7 in the Lancet. Incidence of NASH has increased with the obesity epidemic, affecting people with diabetes, insulin resistance, and/or hypertriglyceridemia. "The condition can smolder for decades without the patient realizing it. A liver is very resilient, so can harbor a lot of inflammation for a long time without specific symptoms," said Dr. Scott L. Friedman, Dean, Therapeutic Discovery, Professor, Medicine, Liver Diseases, Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai. Learn more
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
